Literature DB >> 14502254

Consequences of interactions between the bone marrow stroma and myeloma.

Joshua Epstein1, Shmuel Yaccoby.   

Abstract

Myeloma cells typically reside in the bone marrow. Their presence induces two types of manifestations, both resulting from myeloma plasma cells interactions with cells in their immediate microenvironment: local manifestations such as lytic bone disease, and systemic manifestations such as suppression of the immune system and anemia. Recently, it has been demonstrated that in addition to producing morbid manifestations, these interactions with the bone marrow microenvironment are essential for the survival and growth of the myeloma plasma cells, highlighting a reciprocal relationship that sustains the disease process and promotes progression. The discussion that follows will concentrate on myeloma-induced changes in the bone marrow microenvironment that are important for disease subsistence and progression, with emphasis on data obtained from in vivo and ex vivo studies with primary myeloma cells.

Entities:  

Mesh:

Year:  2003        PMID: 14502254     DOI: 10.1038/sj.thj.6200313

Source DB:  PubMed          Journal:  Hematol J        ISSN: 1466-4860


  20 in total

1.  The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Authors:  Simona Colla; Fenghuang Zhan; Wei Xiong; Xiaosong Wu; Hongwei Xu; Owen Stephens; Shmuel Yaccoby; Joshua Epstein; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

2.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

3.  Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Authors:  Michael F Emmons; Anthony W Gebhard; Rajesh R Nair; Rachid Baz; Mark L McLaughlin; Anne E Cress; Lori A Hazlehurst
Journal:  Mol Cancer Ther       Date:  2011-10-06       Impact factor: 6.261

4.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.

Authors:  Shmuel Yaccoby; Wen Ling; Fenghuang Zhan; Ronald Walker; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

5.  Therapeutic effects of intrabone and systemic mesenchymal stem cell cytotherapy on myeloma bone disease and tumor growth.

Authors:  Xin Li; Wen Ling; Sharmin Khan; Shmuel Yaccoby
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

6.  The ecology of cancer from an evolutionary game theory perspective.

Authors:  Jorge M Pacheco; Francisco C Santos; David Dingli
Journal:  Interface Focus       Date:  2014-08-06       Impact factor: 3.906

7.  Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma.

Authors:  Lijuan Chen; Siqing Wang; Yiming Zhou; Xiaosong Wu; Igor Entin; Joshua Epstein; Shmuel Yaccoby; Wei Xiong; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2009-10-16       Impact factor: 22.113

8.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

9.  Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.

Authors:  Angela Pennisi; Xin Li; Wen Ling; Sharmin Khan; Dana Gaddy; Larry J Suva; Bart Barlogie; John D Shaughnessy; Nazneen Aziz; Shmuel Yaccoby
Journal:  Br J Haematol       Date:  2009-04-08       Impact factor: 6.998

10.  Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells.

Authors:  D Dingli; F A C C Chalub; F C Santos; S Van Segbroeck; J M Pacheco
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.